Global Ophthalmic Drugs Market- Market Overview:

The global ophthalmic drugs market is expected to grow from USD 34 billion in 2022 to USD 62.9 billion by 2030, at a CAGR of 8% during the Projection period 2023-2030. The growth of the ophthalmic drugs market is mainly driven due to the rise in ophthalmic diseases.

Ophthalmic pharmaceuticals are prescribed for the treatment of a variety of eye-related conditions, such as age-related macular degeneration, cytomegalovirus (CMV), diabetic macular edema, color blindness, and diabetic macular edema (AMD). These drugs may be administered through contact lenses, emulsions, ointments, aqueous gels, dendrimers, or nanosuspensions. Neomycin, antibiotics, bacitracin, and polymyxin are all used in the production of ophthalmic medications, which help to slow the spread of bacterial infections in the eyes. They are currently offered commercially in three different formulation types: solid, liquid, and semi-solid. The expansion of the ophthalmic pharmaceuticals market is primarily driven by the increased prevalence of different eye-related ailments, such as vision impairment, glaucoma, and colour blindness, particularly among the growing geriatric population. In accordance with this, growing knowledge of the drug's anti-inflammatory qualities is encouraging demand for it to treat scleritis, cystoid macular edoema, and uveitis problems. Additionally, the market expansion is being supported by the substantial financing and supportive measures being implemented by the governments of numerous nations to stimulate the creation of efficient ophthalmic medications with novel formulations and combinations. Additional growth-promoting elements include substantial technological developments, such as the development of gene-drug therapy for the diagnosis and treatment of hereditary ophthalmic, neurovascular retinal, and retinoblastoma problems. Furthermore, the simple accessibility of ophthalmic medications in the forms of eye solutions, drops, capsules, pills, gels, and ointments via several online and offline distribution channels is fostering market expansion. A favorable outlook for the market is being created by additional variables including major pharmaceutical industry expansion and expanding research and development (R&D) activity to provide efficient ocular drug delivery systems (ODDS).

Sample Request: - Global Ophthalmic Drugs Market

Market Dynamics:

Drivers:                          

• The rise in Government Initiatives

The World Health Organization (WHO) and international eye health associations are aggressively addressing eye health care and advancing the awareness, diagnosis, and treatment of a number of eye disorders, including eye infections. For instance, the International Agency for the Prevention of Blindness (IAPB) and the World Health Organization (WHO) launched the global campaign VISION 2020 in 1999 with the goal of eradicating preventable or treatable eye illnesses by the year 2020. In order to accomplish this, VISION 2020 works to promote the creation and implementation of long-lasting national eye care initiatives built on the following three pillars: infrastructure and technology development, disease control that is cost-effective, the development of human resources, and primary health care delivery principles.

Restraints:

• Lack of Awareness

The prevalence of blindness is often less than 0.5 percent, and occasionally much less, in developed nations. In many developing nations, the prevalence of blindness reaches 1% to 2%. At least six times as many people experience reduced vision, which can substantially hinder personal functioning, including work. As a result, 200 million more individuals are unable to fully engage in labour, and approximately 30 million people, especially in the world's poorer nations, remain (to a large extent unnecessary) blind.

Opportunities:

• Technological Advancements

Numerous pathogens, such as bacteria, amoeba, viruses, and fungi, are capable of causing eye infections. Highly contagious bacterial and viral conjunctivitis can be brought on by a variety of common pathogens, such as the adenovirus, rubella, herpes, staphylococcus aureus, measles, and streptococcus pneumonia. Even though antibiotics are rarely required to treat common eye infections, 60% of patients in the U.S. currently receive prescriptions for antibiotic eye drops. Leading firms in the diagnostics sector are concentrating on the creation and marketing of quick point-of-care diagnostic tools for eye infections. The quick procedure is anticipated to improve the precise use of anti-infective treatments. In the case of adenoviral conjunctivitis, for instance, AdenoPlus is a point-of-care diagnostic, single-use test. AdenoPlus can identify the hexon protein, which is present in the adenovirus serotypes.

Challenges:

• Rising Cataracts Cases

20 million individuals are blind due to cataracts worldwide, while emerging nations account for a disproportionately high percentage of cases (more than 50%). Over 1 billion cases of vision impairment or blindness that could have been avoided or that have not yet been handled affected at least 2.2 billion people worldwide in 2019, according to the WHO. A lack of knowledge regarding disease diagnosis and treatment may impede market expansion.

Segmentation Analysis:

The global ophthalmic drugs market has been segmented based on drug class, disease, dosage forms, and regions.

By Drug Class

The drug class segment is anti-inflammatory, anti-glaucoma, anti-VEGF agents, antiallergy, and others. The anti-VEGF agent segment led the largest share of the ophthalmic drugs market with a market share of around 40% in 2022.  Rising anti-VEGF agent usage and demand, as well as the presence of major market players with extensive product lines, all contribute to the segment's growth. For instance, Genentech USA's LUCENTIS is a prescription drug for the management of individuals with myopic choroidal neovascularization, AMD, and diabetic retinopathy. Furthermore, Avastin, LUCENTIS, and other market leaders performed well, which is another factor contributing to the segment's growth. The attention of stakeholders on the development of treatments with prolonged action is expanding because the current class of anti-VEGF drugs is effective but short-lived. Opthea, Lupin Limited, and Kodiak Sciences Inc. are a few businesses with exciting pipeline products.

By Disease

The disease segment is glaucoma, eye allergy, eye infection, uveitis, dry eye, retinal disorders, and others. The retinal disorders segment led the largest share of the ophthalmic drugs market with a market share of around 35% in 2022. Because of things like diabetic retinopathy and the rising prevalence of macular degeneration. For instance, in 2022, it was predicted that over 11 million people had some kind of AMD, and is expected to reach 22 million by 2050, according to amplified eye care. Additionally, the presence of cutting-edge pipeline pharmaceuticals and the rising sales volume of ophthalmic medications are projected to support segment demand. The market is expanding as a result of increased financing for the development of treatments in the sector. For instance, Trinity Researchers won USD 3.14 million in funding in September 2022 to work with organizations like Eli Lilly and Roche to discover a therapy for the illness.

By Dosage Forms

The dosage forms segment is eye solutions & suspensions, eye drops, gels, capsules and tablets, and ointments. The eye drops segment led the largest share of the ophthalmic drugs market with a market share of around 36% in 2022. The expanding OTC availability of eye drops, patient compliance issues, and the prevalence of eye illnesses all influence the eye drop market's growth. In addition, it is predicted that new product introductions with altered formulations would meet market demand. For instance, Alcon announced the release of their cutting-edge Systane Complete preservative-free eye drop in January 2022. Additionally, it is projected that the availability of cutting-edge technologies to improve bioavailability and physiochemical stability will fuel segment demand. For instance, Bosch and Lomb announced the launch of their hydration lubricant eye drop Biotrue in the United States in July 2021. This product is free of preservatives and comes from a natural source.

Global Ophthalmic Drugs Market - Sales Analysis.

The sale of the opthalmic drugs market expanded at a CAGR of 6% from 2016 to 2022.

To treat ocular disorders or reestablish normal eye function, ophthalmic eye drops are utilized to administer drugs locally in the ocular cavities. Topical instillation of eye drops is the most popular and straightforward method of ocular drug delivery, and it serves as the preferred course of treatment. Globally, it is anticipated that eye infections will become more common and more severe. The global market for ophthalmic eye drops is projected to grow as new pathogens, an increase in post-operative eye infections, and poor eye hygiene are predicted to do so. The market for ophthalmic medications is driven by an increase in occurrences of eye-related illnesses. The market for ophthalmic medications is growing because of the variety of reasons that can lead to eye disorders, such as inflammation, traumas, genetic predispositions, medical conditions, environmental stimuli, and others.

The demand is expected to increase as a result of rising research and development efforts to create and introduce novel ophthalmic medications, as well as a number of strategic initiatives anticipated by the major players. Additionally, the ophthalmic medications market is projected to rise as a result of unmet needs in ophthalmology. Nearly 2.2 billion people are predicted to have distant or near vision impairment disorders, and of these, at least half, or 1 billion instances, can be avoided with the aid of adequate treatment, according to the World Health Organization's October 2021 report on blindness and vision impairment. High age is the main factor in blindness and vision impairment. The financial burden on the governments is increasing as a result of this high incidence.

Thus, owing to the aforementioned factors, the global opthalmic drugs market is expected to grow at a CAGR of 8% during the Projection period from 2023 to 2030.

By Regional Analysis:

The regions analyzed for the opthalmic drugs market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America region dominated the opthalmic drugs market and held a 37% share of the market revenue in 2022.

• The North America region witnessed a major share. Increased eye illness prevalence and growing public knowledge of eye ailments are factors in the region's growth. Additionally, it is projected that increased research and development by major firms will support regional prosperity. Furthermore, there are notable players like Bausch and Lomb, Pfizer Inc., and Alcon present. For instance, Harrow Health Inc. declared in June 2022 that MAXITROL and IOPIDINE 1% are now sold commercially in the United States. The Prescription Drug User Fee Act's new FDA guidelines offer a structured method for weighing the risks and advantages of these ophthalmic medicines in clinical studies.
• Asia-Pacific is anticipated to experience significant growth during the Projection period. Due to factors such as an aging population, an increase in the prevalence of eye problems, and the presence of major players, the ophthalmic pharmaceuticals market is predicted to develop at the quickest rate in the Asia-Pacific region. For instance, 4.3 billion people, or 60% of the world's population, reside in the Asia-Pacific area, according to the United Nations Population Fund's (UNPF) 2021 report. Additionally, the region has the largest prevalence of eye problems, which is a significant factor in the growth of the ophthalmic pharmaceuticals market in the Asia-Pacific region, according to the same source.

Global Ophthalmic Drugs Market - Country Analysis:

• Germany

Germany's ophthalmic drugs market size was valued at USD 0.25 billion in 2022 and is expected to reach USD 0.60 billion by 2030, at a CAGR of 6.6% from 2023 to 2030. The government provides the majority of the funding for the universal, multi-payer German healthcare system. It is one of the world's most effective healthcare systems. Germany has the greatest level of expenditure in all of Europe, which is not surprising. The market for ophthalmic eye drops has a tremendous possibility to expand due to the presence of multiple significant competitors, the rising prevalence of eye infections, technical improvements, and increased R&D in the nation.

• China

China’s ophthalmic drugs market size was valued at USD 0.46 billion in 2022 and is expected to reach USD 0.92 billion by 2030, at a CAGR of 6.9% from 2023 to 2030. The market in the region under study is also anticipated to grow as a result of the rising number of product and medicine launches and the growing emphasis of businesses on research and development operations. For instance, Arctic Vision's Investigational New Drug (IND) application for a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) to treat presbyopia was authorized by the China National Medical Products Administration's Center for Drug Evaluation in September 2021. (CDE, NMPA).

• India

India's ophthalmic drugs market size was valued at USD 0.39 billion in 2022 and is expected to reach USD 0.98 billion by 2030, at a CAGR of 6.3% from 2023 to 2030. Due to the increased awareness of eye illnesses, the region's strong healthcare infrastructure, and the presence of important companies like Pfizer, Inc., and Alcon.

Key Industry Players Analysis:

To increase their market position in the global opthalmic drugs market business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, product developments, collaborations, partnerships, joint ventures, etc.       

• Novartis AG
• Biomedica
• Akorn, Inc.
• C2 PHARMA
• Bausch & Lomb
• AdvaCare Pharma
• Iskon Remedies
• Kraeber GmbH
• Berry Global Inc.
• HANSHIN GROUP
• Bormioli Pharma
• Nolato AB
• Gerresheimer AG
• WG Pro-Manufacturing Inc.
• Aptar Group Inc.
• Adelphi Healthcare Packaging
• Amcor Plc.

Latest Development:

• In April 2022, In order to lower eye pressure in patients with ocular hypertension (high eye pressure) in the United States, Sandoz, a Novartis company, introduced its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%. This generic version of AbbVie's COMBIGAN has an AB rating.
• In March 2022, Seven trademark ophthalmic medications were purchased by Théa Pharma from Akorn Operating Company LLC. The agreement enhances Théa's standing as a key supplier of goods created to meet the needs of eye care professionals across the United States.

Report Metrics

Report Attribute	Details
Study Period	2022-2030
Base year	2022
CAGR (%)	8%
Market Size	34 billion in 2022
Projection period	2023-2030
Projection unit	Value (USD)
Segments covered	By Drug Class, By Disease, By Dosage Form, and By Region.
Report Scope	Revenue Projection, competitive landscape, company ranking, growth factors, and trends
Companies covered	Novartis AG, Biomedica, Akorn, Inc., C2 PHARMA, Bausch & Lomb, AdvaCare Pharma, Iskon Remedies, Kraeber GmbH, Berry Global Inc., HANSHIN GROUP, Bormioli Pharma, Nolato AB, Gerresheimer AG, WG Pro-Manufacturing Inc., Aptar Group Inc., Adelphi Healthcare Packaging, and Amcor Plc.
By Drug Class	Anti-Inflammatory Anti-Glaucoma Anti-VEGF Agents Antiallergy Others
By Disease	Glaucoma Eye Allergy Eye Infection Uveitis Dry Eye Retinal Disorders Others
By Dosage Form	Eye Solutions & Suspensions Eye Drops Gels Capsules and Tablets Ointments
Regional scope	North America Europe Asia-Pacific South America Middle East and Africa

Scope of the Report

Global Ophthalmic Drugs Market  By Drug Class:

• Anti-Inflammatory
• Anti-Glaucoma
• Anti-VEGF Agents
• Antiallergy
• Others

Global Ophthalmic Drugs Market  By Disease :

• Glaucoma
• Eye Allergy
• Eye Infection
• Uveitis
• Dry Eye
• Retinal Disorders
• Others

Global Ophthalmic Drugs Market By Dosage Form:

• Eye Solutions & Suspensions
• Eye Drops
• Gels
• Capsules and Tablets
• Ointments

Global Ophthalmic Drugs Market By Region:

• North America
  • USA
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
• Asia-Pacific
  • Japan
  • China
  • India
  • Korea
  • Southeast Asia
• South America
  • Brazil
  • Peru
• Middle East and Africa
  • UAE
  • South Africa
  • Saudi Arabia

Political Factors- The opthalmic drugs market should carefully consider the concerns made by pressure groups, social and environmental activists, and labour unions because they have a considerable impact on how regulations are developed. The opthalmic drugs market's capacity for civic participation and the achievement of long-term company goals may be improved by close collaboration with these groups. A strong governance framework and a democratic political environment also enhance the business environment for market places like the ophthalmic drugs market.

Economic Factors- A country's economic development has a direct impact on organisational performance. The opthalmic drugs market has several opportunities to grow as a result of developing economies. In a similar vein, understanding the stage of the industrial lifecycle is crucial. Entry into mature industries may be more challenging than entry into enterprises in the growth stage due to market saturation. The amount of money spent by the government of the host nation on the construction of essential infrastructure also has an effect on the financial performance of the opthalmic drugs market. A developed infrastructure makes it easier to conduct business, which also increases the possibility for the gold sector in that country to thrive.

Social factors- Changes in demographic trends, such as population ageing, migration patterns, and socioeconomic considerations, are of the utmost importance for marketplaces like the ophthalmic drugs market. The opthalmic drugs market can choose the appropriate market segment or market segments with considerable growth potential by carefully studying the demographic parameters. Additionally, migration affects company and marketing strategy. It is critical for the opthalmic drugs market to comprehend the general public's perception of migration because it may influence firms' capacity to hire foreign management in the host country.

Technological Factors- The opthalmic drugs market needs to understand how new technologies affect its value chain and present cost structure. To do this, it needs to take into account both the local and global investments made by competitors. Research and development efforts are essential in a situation where creative disruption is common. To maximise revenues and reinvest those earnings in disruptive technologies in the future, the opthalmic drugs market should make investments in disruptive technologies today.

Environmental Factors- More people are choosing to use green or eco-friendly products. The market for ophthalmic drugs can grab this opportunity and use green business practises to win over stakeholders. Due to regulatory organisations' emphasis on assuring compatibility with environmental requirements, priorities for product innovation are changing. Environmental friendliness must be prioritised over conventional value propositions in the opthalmic drugs market's marketing plan. If the opthalmic drugs market regularly depletes its resources, it may come under fire from the media, environmental groups, consumers, and the general public. The opthalmic drugs market must investigate the nation's unique environmental regulations in order to ascertain which resources (such as water, power, etc.) are scarce or which species are in danger of becoming extinct owing to misuse.

Legal Factors- The opthalmic drugs market must adhere to the employee/labor health and safety standards because certain countries have strict laws protecting worker safety. The opthalmic drugs market has an ethical and moral obligation to give its employees a safe place to work. Similarly to this, anti-discrimination laws (such as equal employment opportunity laws) must also be carefully taken into account when creating human resource practices because discriminatory lawsuits against employers harm the organization's reputation and impair its ability to attract and retain talent.

1. Introduction
   • 1. Objectives of the Study
   • 2. Market Definition
   • 3. Research Scope
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
   • 1. Porter’s Five Forces Analysis
   • 2. Value Chain Analysis
   • 3. Top Investment Pockets
     • 3.1. Market Attractiveness Analysis By Drug Class
     • 3.2. Market Attractiveness Analysis By Disease
     • 3.3. Market Attractiveness Analysis By Dosage Form
     • 3.4. Market Attractiveness Analysis By Region
   • 4. Industry Trends
5. Market Dynamics
   • 1. Market Evaluation
   • 2. Drivers
     • 2.1. The rise in Government Initiatives
   • 3. Restraints
     • 3.1. Lack of Awareness
   • 4. Opportunities
     • 4.1. Technological Advancements
   • 5. Challenges
     • 5.1. Rising Cataracts Cases

6. Global Ophthalmic Drugs Market Analysis and Projection, By Drug Class
   • 1. Segment Overview
   • 2. Anti-Inflammatory
   • 3. Anti-Glaucoma
   • 4. Anti-VEGF Agents
   • 5. Antiallergy
   • 6. Others
7. Global Ophthalmic Drugs Market Analysis and Projection, By Disease
   • 1. Segment Overview
   • 2. Glaucoma
   • 3. Eye Allergy
   • 4. Eye Infection
   • 5. Uveitis
   • 6. Dry Eye
   • 7. Retinal Disorders
   • 8. Others
8. Global Ophthalmic Drugs Market Analysis and Projection, By Dosage Form
   • 1. Segment Overview
   • 2. Eye Solutions & Suspensions
   • 3. Eye Drops
   • 4. Gels
   • 5. Capsules and Tablets
   • 6. Ointments
9. Global Ophthalmic Drugs Market Analysis and Projection, By Regional Analysis
   • 1. Segment Overview
   • 2. North America
     • 2.1. U.S.
     • 2.2. Canada
     • 2.3. Mexico
   • 3. Europe
     • 3.1. Germany
     • 3.2. France
     • 3.3. U.K.
     • 3.4. Italy
     • 3.5. Spain
   • 4. Asia-Pacific
     • 4.1. Japan
     • 4.2. China
     • 4.3. India
   • 5. South America
     • 5.1. Brazil
   • 6. Middle East and Africa
     • 6.1. UAE
     • 6.2. South Africa

10. Global Ophthalmic Drugs Market-Competitive Landscape
    • Overview
    • Market Share of Key Players in the Ophthalmic Drugs Market
      • 2.1. Global Company Market Share
      • 2.2. North America Company Market Share
      • 2.3. Europe Company Market Share
      • 2.4. APAC Company Market Share
    • Competitive Situations and Trends
      • 3.1. Product Launches and Developments
      • 3.2. Partnerships, Collaborations, and Agreements
      • 3.3. Mergers & Acquisitions
      • 3.4. Expansions

11. Company Profiles
    • Novartis AG
      • 1.1. Business Overview
      • 1.2. Company Snapshot
      • 1.3. Company Market Share Analysis
      • 1.4. Company Product Portfolio
      • 1.5. Recent Developments
      • 1.6. SWOT Analysis
    • Biomedica
      • 2.1. Business Overview
      • 2.2. Company Snapshot
      • 2.3. Company Market Share Analysis
      • 2.4. Company Product Portfolio
      • 2.5. Recent Developments
      • 2.6. SWOT Analysis
    • Akorn, Inc.
      • 3.1. Business Overview
      • 3.2. Company Snapshot
      • 3.3. Company Market Share Analysis
      • 3.4. Company Product Portfolio
      • 3.5. Recent Developments
      • 3.6. SWOT Analysis
    • C2 PHARMA
      • 4.1. Business Overview
      • 4.2. Company Snapshot
      • 4.3. Company Market Share Analysis
      • 4.4. Company Product Portfolio
      • 4.5. Recent Developments
      • 4.6. SWOT Analysis
    • Bausch & Lomb
      • 5.1. Business Overview
      • 5.2. Company Snapshot
      • 5.3. Company Market Share Analysis
      • 5.4. Company Product Portfolio
      • 5.5. Recent Developments
      • 5.6. SWOT Analysis
    • AdvaCare Pharma
      • 6.1. Business Overview
      • 6.2. Company Snapshot
      • 6.3. Company Market Share Analysis
      • 6.4. Company Product Portfolio
      • 6.5. Recent Developments
      • 6.6. SWOT Analysis
    • Iskon Remedies
      • 7.1. Business Overview
      • 7.2. Company Snapshot
      • 7.3. Company Market Share Analysis
      • 7.4. Company Product Portfolio
      • 7.5. Recent Developments
      • 7.6. SWOT Analysis
    • Kraeber GmbH
      • 8.1. Business Overview
      • 8.2. Company Snapshot
      • 8.3. Company Market Share Analysis
      • 8.4. Company Product Portfolio
      • 8.5. Recent Developments
      • 8.6. SWOT Analysis
    • Berry Global Inc.
      • 9.1. Business Overview
      • 9.2. Company Snapshot
      • 9.3. Company Market Share Analysis
      • 9.4. Company Product Portfolio
      • 9.5. Recent Developments
      • 9.6. SWOT Analysis
    • HANSHIN GROUP
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Bormioli Pharma
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Nolato AB
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Gerresheimer AG
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • WG Pro-Manufacturing Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Aptar Group Inc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Adelphi Healthcare Packaging
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis
    • Amcor Plc.
      • Business Overview
      • Company Snapshot
      • Company Market Share Analysis
      • Company Product Portfolio
      • Recent Developments
      • SWOT Analysis

List of Table

1. Global Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
2. Global Anti-Inflammatory, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
3. Global Anti-Glaucoma, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
4. Global Anti-VEGF Agents, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
5. Global Antiallergy, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
6. Global Others, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
7. Global Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
8. Global Glaucoma, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
9. Global Eye Allergy, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
10. Global Eye Infection, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
11. Global Uveitis, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
12. Global Dry Eye, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
13. Global Retinal Disorders, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
14. Global Others, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
15. Global Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
16. Global Eye Solutions & Suspensions, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
17. Global Eye Drops, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
18. Global Gels, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
19. Global Capsules and Tablets, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
20. Global Ointments, Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
21. Global Ophthalmic Drugs Market, By Region, 2023–2030 (USD Billion)
22. North America Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
23. North America Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
24. North America Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
25. USA Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
26. USA Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
27. USA Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)  
28. Canada Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
29. Canada Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
30. Canada Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
31. Mexico Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
32. Mexico Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
33. Mexico Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
34. Europe Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
35. Europe Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
36. Europe Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
37. Germany Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
38. Germany Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
39. Germany Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
40. France Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
41. France Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
42. France Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
43. UK Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
44. UK Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
45. UK Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
46. Italy Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
47. Italy Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
48. Italy Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
49. Spain Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
50. Spain Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
51. Spain Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
52. Asia Pacific Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
53. Asia Pacific Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
54. Asia Pacific Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
55. Japan Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
56. Japan Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
57. Japan Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
58. China Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
59. China Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
60. China Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
61. India Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
62. India Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
63. India Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
64. South America Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
65. South America Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
66. South America Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
67. Brazil Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
68. Brazil Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
69. Brazil Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
70. Middle East and Africa Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
71. Middle East and Africa Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
72. Middle East and Africa Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
73. UAE Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
74. UAE Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
75. UAE Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)
76. South Africa Ophthalmic Drugs Market, By Drug Class, 2023–2030 (USD Billion)
77. South Africa Ophthalmic Drugs Market, By Disease, 2023–2030 (USD Billion)
78. South Africa Ophthalmic Drugs Market, By Dosage Form, 2023–2030 (USD Billion)

List of Figures 

1. Global Ophthalmic Drugs Market Segmentation
2. Ophthalmic Drugs Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Ophthalmic Drugs Market Attractiveness Analysis By Drug Class
9. Global Ophthalmic Drugs Market Attractiveness Analysis By Disease
10. Global Ophthalmic Drugs Market Attractiveness Analysis By Dosage Form
11. Global Ophthalmic Drugs Market Attractiveness Analysis By Region
12. Global Ophthalmic Drugs Market: Dynamics
13. Global Ophthalmic Drugs Market Share By Drug Class (2023 & 2030)
14. Global Ophthalmic Drugs Market Share By Disease (2023 & 2030)
15. Global Ophthalmic Drugs Market Share By Dosage Form (2023 & 2030)
16. Global Ophthalmic Drugs Market Share by Regions (2023 & 2030)
17. Global Ophthalmic Drugs Market Share by Company (2021)